Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Toney

Physician Assistant Knoxville, TN Physician Assistant

NPI 1629493614 CMS profile 10907233

103 Midlake Dr, Knoxville, TN 37918

Open in the dashboard

General payments

$7,776

468 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Toney of Knoxville, TN is reported in the CMS Open Payments database as having received $7,776 across 468 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,949 105
2024 General $1,983 120
2023 General $1,853 111
2022 General $1,145 75
2021 General $845 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Toney
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ashley Toney were reported at $1,949. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ashley Toney Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $845 $132 $37–$438 $132
2022 $1,145 $155 $48–$522 $149
2023 $1,853 $167 $52–$557 $160
2024 $1,983 $178 $55–$600 $164
2025 $1,949 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,065 58 payments
  2. AbbVie, Inc. $836 59 payments
  3. GlaxoSmithKline, LLC. $791 49 payments
  4. Pfizer Inc. $646 44 payments
  5. AstraZeneca Pharmaceuticals LP $466 15 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $440 21 payments
  7. Lilly USA, LLC $279 27 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $248 18 payments
  9. Janssen Pharmaceuticals, Inc $222 12 payments
  10. E.R. Squibb & Sons, L.L.C. $221 15 payments
  11. Other $2,563 150 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,776 468 payments
Products named General payments · program years 2021–2025
  1. Ozempic $766 37 payments
  2. RYBELSUS $715 35 payments
  3. TRELEGY ELLIPTA $512 32 payments
  4. XIFAXAN $440 21 payments
  5. UBRELVY $429 32 payments
  6. NURTEC ODT $390 27 payments
  7. AIRSUPRA $378 10 payments
  8. ZAVZPRET $357 25 payments
  9. VRAYLAR $322 21 payments
  10. Wegovy $277 19 payments
  11. Other $6,842 403 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 100 drugs

Part D claims

3,353

Median for Physician Assistant: 241

Drug cost

$269,687

Median for Physician Assistant: $4,110

Branded share of claims

14.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 40 $55,668
Ozempic Semaglutide Brand 25 $50,683
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 33 $34,210
Eliquis Apixaban Brand 34 $31,531
Jardiance Empagliflozin Brand 11 $18,099
Linzess Linaclotide Brand 25 $14,998
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 13 $14,216
Qulipta Atogepant Brand 11 $13,322
Entresto Sacubitril/Valsartan Brand 12 $8,102
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 14 $2,572

The 10 drugs with the highest cost, of 100 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 97 billing codes

Paid by Medicare

$32,759

Of which drugs: $3,935

Medicare patients

202

Average age 73

Services billed

1,460

109 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 35%
Chronic kidney disease 34%
Ischemic heart disease 25%
Depression 23%
Atrial fibrillation 22%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 20 20 $1,555
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 11 36 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $164
$164 — —
VRAYLAR
  • AbbVie, Inc. $133
$133 — —
Wegovy
  • Novo Nordisk Inc $107
$107 — —
RYBELSUS
  • Novo Nordisk Inc $100
$100 — —
Ozempic
  • Novo Nordisk Inc $100
$100 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

468 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record